文献速递湿疹皮炎与荨麻疹

度普利尤单抗降低特应性皮炎患儿线性生长受限风险:队列研究

Decreased risk of reduced linear growth among children with atopic dermatitis receiving dupilumab: A cohort study.
PubMed 文献 · J Am Acad Dermatol · 2025-08-18

该回顾性队列研究基于TriNetX美国协作网络2018年1月至2023年12月数据,纳入745,046名18岁以下儿童。特应性皮炎(AD)患儿相比倾向评分匹配的非AD对照,身高低于第5、25、50百分位的风险显著升高;在AD患儿中,启动度普利尤单抗(DUPI)治疗相比传统系统性免疫调节剂,身高降至上述百分位以下的风险显著降低。

要点

  • AD患儿身高低于第5、25、50百分位的风险均显著高于匹配对照。
  • DUPI治疗与AD患儿身高低于第5、25、50百分位的风险显著降低相关。
  • 男性、6岁以上及BMI≥20的AD患儿中DUPI的生长保护关联最强。

核心结论

  • AD患儿存在线性生长受损风险增加,而DUPI治疗可能减弱这一风险。

研究设计与样本

  • 利用TriNetX美国协作网络的回顾性队列研究,纳入2018年1月至2023年12月期间18岁以下儿童745,046名。
  • AD患儿与倾向评分匹配的非AD对照比较身高百分位风险;AD患儿中采用目标试验模拟框架比较DUPI与传统系统性免疫调节剂。
  • 采用Cox比例风险模型估计5年随访期内身高降低的相对风险(RR)。

主要发现

  • AD患儿相比匹配对照,身高低于第5百分位RR 1.15(95%CI 1.12-1.18),低于第25百分位RR 1.13(95%CI 1.08-1.21),低于第50百分位RR 1.22(95%CI 1.20-1.25)。
  • AD患儿中,DUPI治疗相比传统系统性免疫调节剂,身高低于第5百分位RR 0.69(95%CI 0.57-0.84,P<.001),低于第25百分位RR 0.70(95%CI 0.54-0.91,P<.001),低于第50百分位RR 0.74(95%CI 0.58-0.95,P<.001)。
  • AD患儿身高风险升高在男性和6岁以上儿童中尤为明显;睡眠障碍和糖皮质激素使用为潜在效应修饰因素。
  • DUPI与身高百分位降低的负向关联在男性、6岁以上及BMI≥20的儿童中最强。

临床怎么用

  • 对AD患儿应常规监测生长发育,尤其关注男性和6岁以上儿童。
  • 在AD系统治疗选择中,可考虑DUPI对线性生长的潜在保护获益。

局限性

  • 数据缺乏AD严重程度信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Existing studies have shown inconsistent results regarding the association between atopic dermatitis (AD) and linear growth, and the relationship between dupilumab (DUPI) use and height remains unclear. OBJECTIVE: This study examines the association between AD and reduced stature in children and evaluates the influence of DUPI on growth outcomes in real-world clinical settings. METHODS: Utilizing the TriNetX US Collaborative Network, we conducted a retrospective cohort study from January 2018 to December 2023 involving children aged <18 years. Children with AD were compared to propensity score-matched non-AD controls to evaluate the risk of falling below the 5th, 25th, and 50th height percentiles. Among children with AD, a target trial emulation framework was applied to compare growth outcomes between those initiating DUPI and those receiving conventional systemic immunomodulators. Cox proportional hazards models, adjusted for relevant confounders, were used to estimate relative risks (RRs) for reduced stature over a 5-year follow-up period. RESULTS: The study included 745,046 pediatric individuals. Children with AD exhibited a significantly increased risk of reduced height compared to matched controls (<5th percentile: RR 1.15, 95% CI 1.12-1.18; <25th percentile: RR 1.13, 95% CI 1.08-1.21; <50th percentile: RR 1.22, 95% CI 1.20-1.25), with elevated risks particularly evident in males and those aged over 6 years. Sleep disturbance and corticosteroid use emerged as potential effect modifiers. Additionally, among children with AD, treatment with DUPI was associated with a significantly lower risk of falling below the 5th (RR 0.69, 95% CI 0.57-0.84, P < .001), 25th (RR 0.70, 95% CI 0.54-0.91, P < .001), and 50th (RR 0.74, 95% CI 0.58-0.95, P < .001) height percentiles, with the strongest associations observed in males, children over 6 years, and those of body mass index ≥20. LIMITATIONS: The data lack AD severity. CONCLUSIONS: Children with AD are at increased risk of impaired linear growth; however, treatment with DUPI appears to attenuate this risk. These findings highlight the potential growth-preserving benefits of DUPI in the management of pediatric AD and emphasize the importance of routine growth monitoring in this population.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Chen TL, Ma SH, Ou WF, et al. Decreased risk of reduced linear growth among children with atopic dermatitis receiving dupilumab: A cohort study. J Am Acad Dermatol. 2025. PMID: 40835132. doi:10.1016/j.jaad.2025.08.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。